Pancreatic Cancer Research

ResearcherUniversity of California, IrvineActive in the last 2 years

Farshid Dayyani

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4970-5189; OpenAlex author ID A5022820783. Sources: OpenAlex.

Their work

Papers
11 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
48
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 2 papers · 2022: 1 paper · 2023: 1 paper · 2024: 2 papers · 2025: 2 papers · 2026: 2 papers

Papers 11

  1. Outcomes of Irreversible Electroporation for Treatment of Refractory Locally Advanced Pancreatic Cancer. Co-author DOI 10.1016/j.jvir.2026.108954↗
  2. Impact of UGT1A1*28 polymorphism in patients with metastatic pancreatic ductal adenocarcinoma treated with NALIRIFOX in the NAPOLI 3 trial. Co-author DOI 10.1080/14796694.2026.2664776↗
  3. Predicting Benefit of Neoadjuvant Chemotherapy and Elective Nodal Irradiation in Pancreatic Adenocarcinoma: A Supervised Machine Learning Approach. Co-author DOI 10.1002/cam4.71447↗
  4. Replacing Liposomal Irinotecan With Standard Irinotecan in Pancreatic Adenocarcinoma: Should We Follow Suit and Substitute Without Dispute? Last author DOI 10.1097/mpa.0000000000002490↗
  5. Association of personalized and tumor-informed ctDNA with patient survival outcomes in pancreatic adenocarcinoma. Co-author DOI 10.1093/oncolo/oyae155↗
  6. Hereditary Cancer Clinics Improve Adherence to NCCN Germline Testing Guidelines for Pancreatic Cancer. Co-author DOI 10.6004/jnccn.2023.7333↗
  7. Second-line treatment options for patients with metastatic pancreatic ductal adenocarcinoma: A systematic literature review. Co-author DOI 10.1016/j.ctrv.2022.102502↗
  8. BRCA-Mutated Pancreatic Cancer: From Discovery to Novel Treatment Paradigms. Co-author DOI 10.3390/cancers14102453↗
  9. Population pharmacokinetics of liposomal irinotecan in patients with cancer and exposure-safety analyses in patients with metastatic pancreatic cancer. Co-author DOI 10.1002/psp4.12725↗
  10. First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II study. Co-author DOI 10.1016/j.ejca.2021.03.028↗
  11. Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001). Co-author DOI 10.1007/s00280-014-2499-4↗

Closest collaborators

The 25 strongest of 48 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jennifer Brooke Valerin · 4 shared papers, 2022–2025 · strength 0.98
  2. Zev A. Wainberg · 4 shared papers, 2021–2026 · strength 0.78
  3. Fa-Chyi Lee · 3 shared papers, 2022–2026 · strength 0.66
  4. David K. Imagawa · 2 shared papers, 2025–2026 · strength 0.53
  5. Teresa Mercade Macarulla · 3 shared papers, 2021–2023 · strength 0.50
  6. Maen Abdelrahim · 2 shared papers, 2024–2026 · strength 0.43
  7. Naomie Devico Marciano · 2 shared papers, 2022–2024 · strength 0.37
  8. May Thet Cho · 2 shared papers, 2022–2024 · strength 0.37
  9. Aditya Mahadevan · 1 shared paper, 2025 · strength 0.37
  10. Nadine Abi‐Jaoudeh · 1 shared paper, 2026 · strength 0.29
  11. Jennifer Brooke Goldstein · 1 shared paper, 2026 · strength 0.29
  12. Ricardo Azevedo · 1 shared paper, 2026 · strength 0.29
  13. Andrea J. Bullock · 1 shared paper, 2026 · strength 0.28
  14. Hassan A. Hatoum · 1 shared paper, 2026 · strength 0.28
  15. Eileen Mary O'Reilly · 1 shared paper, 2026 · strength 0.28
  16. Gazala Naaz Khan · 1 shared paper, 2026 · strength 0.28
  17. Steven Neema Seyedin · 1 shared paper, 2025 · strength 0.25
  18. Garrett K. Harada · 1 shared paper, 2025 · strength 0.25
  19. Zeljka Jutric · 1 shared paper, 2025 · strength 0.25
  20. David S. Hong · 1 shared paper, 2025 · strength 0.25
  21. Andrew Peter Dean · 2 shared papers, 2021 · strength 0.24
  22. Bin Zhang · 2 shared papers, 2021 · strength 0.24
  23. Tanios Bekaii‐Saab · 2 shared papers, 2021 · strength 0.24
  24. Kabir Mody · 2 shared papers, 2021 · strength 0.24
  25. Claudia Rosso · 1 shared paper, 2024 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.